Management of direct antiviral agent failures.

about

Retreatment Options Following HCV Direct Acting Antiviral Failure.Effectiveness of sofosbuvir/pegylated-interferon plus ribavirin in treatment of hepatitis C virus genotype 4 patients

P2860

Q47306709-0A28A330-17C6-43FB-A2AB-4AA648AD5A67 Q57494344-8B4AA1EB-C87D-4BB7-9E1F-3023C7878852

P2860

Management of direct antiviral agent failures.

Item

http://www.wikidata.org/entity/Q39024201

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Management of direct antiviral agent failures.

@en

Management of direct antiviral agent failures.

@nl

type

Item

label

Management of direct antiviral agent failures.

@en

Management of direct antiviral agent failures.

@nl

prefLabel

Management of direct antiviral agent failures.

@en

Management of direct antiviral agent failures.

@nl

P1476

Management of direct antiviral agent failures

@en

P2093

María Buti

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution

Rapid evolution of RNA genomes

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

Sofosbuvir for previously untreated chronic hepatitis C infection

Replication of hepatitis C virus

Ultra-deep pyrosequencing (UDPS) data treatment to study amplicon HCV minor variants.

Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.

All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.

Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2)

P304

432-438

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3350/CMH.2016.0107

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Rafael Esteban

P577

2016-12-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28081594

http://www.w3.org/2001/XMLSchema#string

P932

5266337

http://www.w3.org/2001/XMLSchema#string

Management of direct antiviral agent failures.

about

P2860

P2860

Management of direct antiviral agent failures.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932